Amgen (AMGN) : Mufg Americas Holdings Corp reduced its stake in Amgen by 3.28% during the most recent quarter end. The investment management company now holds a total of 78,887 shares of Amgen which is valued at $13,602,485 after selling 2,676 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Amgen makes up approximately 0.46% of Mufg Americas Holdings Corp’s portfolio.
Other Hedge Funds, Including , Oppenheimer Co Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 23,997 additional shares and now holds a total of 143,371 shares of Amgen which is valued at $24,721,462. Amgen makes up approx 0.71% of Oppenheimer Co Inc’s portfolio.Copeland Capital Management reduced its stake in AMGN by selling 392 shares or 2.21% in the most recent quarter. The Hedge Fund company now holds 17,355 shares of AMGN which is valued at $3,013,869. Amgen makes up approx 0.20% of Copeland Capital Management’s portfolio.Tokio Marine Asset Management Co Ltd reduced its stake in AMGN by selling 718 shares or 3.32% in the most recent quarter. The Hedge Fund company now holds 20,918 shares of AMGN which is valued at $3,570,284. Amgen makes up approx 0.36% of Tokio Marine Asset Management Co Ltd’s portfolio.Sarasin Partners Llp reduced its stake in AMGN by selling 178,880 shares or 11.92% in the most recent quarter. The Hedge Fund company now holds 1,321,724 shares of AMGN which is valued at $215,348,491. Amgen makes up approx 3.45% of Sarasin Partners Llp’s portfolio.
Amgen opened for trading at $171.48 and hit $174.72 on the upside on Monday, eventually ending the session at $174.58, with a gain of 0.90% or 1.56 points. The heightened volatility saw the trading volume jump to 27,84,334 shares. Company has a market cap of $130,649 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.